CSL Seqirus opens $1 billion vaccine and antivenom manufacturing facility in Melbourne, boosting Australia's sovereign manufacturing capacity and reducing international supply chain reliance.
The opening of this major $1 billion facility significantly boosts Australia's sovereign manufacturing capacity for critical vaccines and antivenoms. This reduces reliance on international supply chains, enhances national biosecurity, and positions CSL Seqirus as a key player in regional and global health security, potentially impacting market dynamics for these essential products.
$1 billion vaccine and antivenom facility opens in Melbourne.
Enhances Australia's onshore manufacturing capabilities.
Reduces reliance on international supply chains.
This facility is located in Melbourne, Australia, and is a significant development for the country's biopharmaceutical manufacturing sector and public health infrastructure.
Reduces reliance on international supply chains.
Key development for national biosecurity.
Sign in to save notes on signals.
Sign In